These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2529825)

  • 41. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue.
    West CP; Baird DT
    Clin Endocrinol (Oxf); 1987 Feb; 26(2):213-20. PubMed ID: 2959405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle.
    Trueman JA; Tillmann V; Cusick CF; Foster P; Patel L; Hall CM; Price DA; Clayton PE
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):223-30. PubMed ID: 12153601
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A multi-centre randomised study to compare the effects of ovarian ablation with Zoladex depot in pre- and perimenopausal patients with advanced breast cancer.
    Tyrrell C
    Horm Res; 1989; 32 Suppl 1():218-20. PubMed ID: 2533154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer.
    Nicholson RI; Walker KJ; Turkes A; Dyas J; Plowman PN; Williams M; Blamey RW
    J Steroid Biochem; 1985 Nov; 23(5B):843-7. PubMed ID: 2934580
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
    Murphy GP; Greco JM; Chin JL; Huben RP; Scott M; deHaan HA
    Urology; 1987 Feb; 29(2):185-90. PubMed ID: 2949417
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist.
    Tuvemo T; Gustafsson J; Proos LA;
    Horm Res; 2002; 57(1-2):27-31. PubMed ID: 12006716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complete estrogen blockade with buserelin and aminoglutethimide for advanced breast cancer: a phase I-II study with long-term hormonal correlations.
    Ferrari V; Zaniboni A; Simoncini E; Marpicati E; Montini E; Moretti R; Marini G
    Chemioterapia; 1988 Dec; 7(6):414-9. PubMed ID: 3146444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
    Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
    Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of the gonadotrophin-releasing hormone agonist 'Zoladex' upon pituitary and gonadal function in hypogonadal (hpg) male mice: a comparison with normal male and testicular feminized (tfm) mice.
    Scott IS; Bennett MK; Porter-Goff AE; Harrison CJ; Cox BS; Grocock CA; O'Shaughnessy PJ; Clayton RN; Craven R; Furr BJ
    J Mol Endocrinol; 1992 Jun; 8(3):249-58. PubMed ID: 1385960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis.
    Maouris P; Dowsett M; Rose G; Edmonds DK; Rothwell C; Robertson WR
    Clin Endocrinol (Oxf); 1990 Oct; 33(4):539-46. PubMed ID: 2146047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison between depot leuprorelin and daily buserelin in IVF.
    Porcu E; Filicori M; Dal Prato L; Fabbri R; Seracchioli R; Colombi C; Flamigni C
    J Assist Reprod Genet; 1995 Jan; 12(1):15-9. PubMed ID: 7580003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer.
    Waxman J; Sandow J; Thomas H; James N; Williams G
    Cancer Chemother Pharmacol; 1989; 25(3):219-20. PubMed ID: 2513141
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
    Nicholson RI; Walker KJ
    Chemioterapia; 1985 Jun; 4(3):249-51. PubMed ID: 3161643
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.
    Ward JA; Robinson J; Furr BJ; Shalet SM; Morris ID
    Cancer Res; 1990 Feb; 50(3):568-74. PubMed ID: 2137024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
    Geldof AA; de Voogt HJ; Rao BR
    Prostate; 1987; 11(3):281-90. PubMed ID: 2960958
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
    Mahler C; Verhelst J; Chaban M; Denis L
    Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
    J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
    Williams G; Kerle D; Griffin S; Dunlop H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Dec; 289(6458):1580-1. PubMed ID: 6239674
    [No Abstract]   [Full Text] [Related]  

  • 60. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.